German Federal Social Court Holds Hearing on Classification of Exoskeleton Medical Devices for People with Spinal Cord Injuries
MARLBOROUGH, Mass. and BERLIN and YOKNEAM ILIT, Israel, Sept. 12, 2022 (GLOBE NEWSWIRE) — ReWalk Robotics, Ltd. (Nasdaq: RWLK) (“ReWalk” or the “Company”), a leading manufacturer of medical robot technology for people with lower extremity disabilities, today announced that the German Federal Social Court has scheduled a hearing for review the decision of whether an exoskeleton medical device should be classified as directly or indirectly compensating for the loss of function of people with spinal cord injury or paraplegia. The hearing is set for November 10, 2022.
The court ruling will establish a new national policy for exoskeleton medical aids and will apply nationwide to all Germans covered by statutory health insurance (SHI). Establishing a legal classification of exoskeletons will provide guidance to patients and insurance companies, establishing a reliable legal basis for the application process for the supply of exoskeletons.
“The myriad of benefits patients experience in regaining the ability to stand and walk again through the use of a ReWalk exoskeleton have clearly shown that restoring walking function after injury to spinal cord is a basic need,” says Larry Jasinski, CEO of ReWalk Robotics. “The German healthcare system has paved the way for the adoption of exoskeletons for people with spinal cord injuries. By establishing a clear classification of exoskeleton medical aids, the court will provide important national guidance to payers and patients in the claim process. care and create a pathway to provide access to this innovative technology to all eligible users in Germany through an established procurement process. We look forward to the upcoming decision.”
For more information on ReWalk Robotics and the ReWalk Exoskeleton, visit rewalk.com.
About ReWalk Robotics Ltd.
ReWalk Robotics Ltd. develops, manufactures and markets wearable robotic exoskeletons for people with lower limb disabilities following spinal cord injury or stroke. ReWalk’s mission is to fundamentally change the quality of life for people with lower extremity disabilities through the creation and development of market-leading robotic technologies. Founded in 2001, ReWalk is headquartered in the United States, Israel and Germany. For more information on ReWalk systems, please visit rewalk.com.
ReStore® is a registered trademark of ReWalk Robotics Ltd. in the United States, Europe and the United Kingdom.
Forward-looking statements
In addition to historical information, this press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995, Section 27A of the United States Securities Act of 1933, as amended, and Section 21E of the US Securities Exchange Act. of 1934, as amended. These forward-looking statements may include projections regarding ReWalk’s future performance and other statements that are not statements of historical fact and, in some instances, may be identified by words such as “anticipate”, “assume”, ” believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “potential”, “predict”, “project”, “future”, “will”, “should”, “should”, “seek” and similar terms or expressions. The forward-looking statements contained in this press release are based on management’s current expectations, which are subject to uncertainties, risks and changes in circumstances that are difficult to predict and many of which are beyond ReWalk’s control Important factors that could cause ReWalk’s actual results to differ materially from those indicated in the forward-looking statements are discussed in more detail in periodic filings by ReWalk with the Securities and Exchange Commission (“SEC”), including the risk factors described under “Risk Factors” in ReWalk’s Annual Report on Forms 10-K and 10-K /A for the year ended December 31, 2021 filed with the SEC and in other documents subsequently filed with or provided to the SEC. Any forward-looking statements made in this press release speak only as of the date hereof. Factors or events that could cause ReWalk’s actual results to differ from the statements contained herein may emerge from time to time, and it is not possible for ReWalk to predict all of them. Except as required by law, ReWalk undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.
Contact Investor:
Almog Adar
Finance director
ReWalk Robotics Ltd.
Such. : +972-4-9590130
Email: [email protected]
Media Contact:
John Tomlin
E: [email protected]
